Evaluation of Convenience and Compliance of the Easypod™ Electronic Self-injector

Key facts

Sponsor

Merck KGaA, Darmstadt, Germany

Principal Investigator

Clément Olivier, MD, LMCC

Merck Serono S.A., Geneva

Enrollment

834 enrolled

Eligibility

2-17 years · All sexes

Timeline

2007 – 2009

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Turner syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07502586
  Turner Syndrome: Genetic Considerations
  Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
• RECRUITINGPHASE3NCT07221851
  Trial Investigating the Efficacy and Safety of Weekly Lonapegsomatropin Compared to Daily Somatropin in Children and Adolescents With Short Stature or Growth Failure Due to Growth Hormone Sufficient Disorders
  Ascendis Pharma A/S
• RECRUITINGNCT07344012
  Parental Project Amongst 93 Patients With Turner Syndrome
  University Hospital, Strasbourg, France
• RECRUITINGPHASE4NCT06834594
  Bleeding Patterns in Sequential and Continuous Progesterone Supplementation in Adolescents With Turner Syndrome
  Children's Mercy Hospital Kansas City
• RECRUITINGNCT06507007
  Genetic and Epigenetic Background of Inner Ear Dysfunction in Turner Syndrome
  Gødstrup Hospital
• RECRUITINGNCT06794190
  Characterization of Hepatopathy in Turner Syndrome: Analysis of Determinants
  IRCCS Azienda Ospedaliero-Universitaria di Bologna
• RECRUITINGPHASE2NCT06668805
  A Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment
  BioMarin Pharmaceutical
• RECRUITINGPHASE2NCT05849389
  Vosoritide for Short Stature in Turner Syndrome
  Roopa Kanakatti Shankar, MBBS, MS

See all trials for Turner syndrome →